Roche under fire again: Mylan launches Herceptin copycat in latest blow to blockbuster trio

herceptin
Mylan said Herceptin biosim Ogivri would launch at a "competitive discount." (Roche)

Much has been made of the challenges Roche's blockbuster oncology troika faces with U.S. biosimilars hitting the market in quick succession. So far, those challengers haven't made much of a dent in Roche's sales stateside––but a new contestant could help tip the scales.

Mylan and Biocon have launched their Herceptin copy, Ogivri, in the U.S., making it the second biosim on the market for Roche's blockbuster breast and stomach cancer drug. 

Mylan said in a release that Ogivri would hit the market at a "competitive discount" to Herceptin but did not disclose the list price for its 420-milligram and 150-milligram vials. 

"With regulatory approval for our biosimilar (Herceptin) in more than 80 countries worldwide, we are bringing vast global biosimilars experience to the U.S. and look forward to continuing our work with all stakeholders in the healthcare system to reduce costs, improve access and advance care," Mylan President Rajiv Malik said in a statement. 

RELATED: Say hello to Roche's worst-case scenario: Teva's Rituxan biosim set to launch in U.S.

Suggested Articles

At one point, Novartis even offered up $90 apiece for the inclisiran developer but would later say even $85 was too much, a securities filing shows.

Sanofi spent months hyping its Tuesday investor event, and new CEO Paul Hudson certainly laid out a different vision for the drugmaker at the confab.

After more than 10 years as partners, Sanofi and Regeneron are splitting up their deal to comarket PCSK9 med Praluent and immunology drug Kevzara.